These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28057178)

  • 1. [Not Available].
    Oudard S; Thibault C; Angelergues A; Tartour E; Timsit MO; Mejean A; Michel C; Vano Y
    Bull Cancer; 2016 Nov; 103 Suppl 1():S144-S150. PubMed ID: 28057178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer immunotherapy.
    May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
    Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer targeting vaccines: surrogate measures of activity.
    Nemunaitis J
    Hum Vaccin Immunother; 2013 Jan; 9(1):213-8. PubMed ID: 23442594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer immunotherapy: the path forward.
    Madan RA; Gulley JL
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):225-230. PubMed ID: 28644303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 9. Current status of immunological approaches for the treatment of prostate cancer.
    Drake CG; Antonarakis ES
    Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of immunological therapies for prostate cancer.
    Antonarakis ES; Drake CG
    Curr Opin Urol; 2010 May; 20(3):241-6. PubMed ID: 20179598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
    Comiskey MC; Dallos MC; Drake CG
    Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
    Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
    Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
    Wei XX; Fong L; Small EJ
    Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
    Gulley JL; Madan RA; Heery CR
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.